Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Annals of Oncology.
Times cited: 35
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Journal of Clinical Oncology.
Times cited: 513
Supportive therapy: Challenges for the '90s-Perspectives in antiemetic therapy.
European Journal of Cancer.
Times cited: 2
- Supportive therapy: Challenges for the '90s - Perspectives in antiemetic therapy. European Journal of Cancer Part A: General Topics. 1992 Conference Paper